PTC Therapeutics, Inc. Share-based Payment Arrangement, Expense
PTC Therapeutics, Inc. (PTCT) reported Share-based Payment Arrangement, Expense of $23.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-07-30
- PTC Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $23.29M, a 25.61% increase year-over-year.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $23.42M, a 29.68% increase year-over-year.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $18.52M, a 7.42% increase year-over-year.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $19.43M, a 1.67% decline year-over-year.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $74.55M, a 0.09% decline from fiscal 2024.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $74.61M, a 26.59% decline from fiscal 2023.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $101.64M, a 7.88% decline from fiscal 2022.
- PTC Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $110.33M, a 6.59% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.29M 10-Q · filed 2026-07-30 | $46.71M 10-Q · filed 2026-07-30 | $65.23M derived: sum of 3 quarters · filed 2026-07-30 | $84.66M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $23.42M 10-Q · filed 2026-05-07 | $41.94M derived: sum of 2 quarters · filed 2026-05-07 | $61.37M derived: sum of 3 quarters · filed 2026-05-07 | $79.91M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | $18.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $37.94M derived: sum of 2 quarters · filed 2026-02-19 | $56.49M derived: sum of 3 quarters · filed 2026-07-30 | $74.55M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $19.43M 10-Q · filed 2025-11-04 | $37.97M derived: sum of 2 quarters · filed 2026-07-30 | $56.03M 10-Q · filed 2025-11-04 | $73.27M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $18.54M 10-Q · filed 2026-07-30 | $36.60M 10-Q · filed 2026-07-30 | $53.84M derived: sum of 3 quarters · filed 2026-07-30 | $73.60M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $18.06M 10-Q · filed 2026-05-07 | $35.30M derived: sum of 2 quarters · filed 2026-05-07 | $55.05M derived: sum of 3 quarters · filed 2026-05-07 | $74.30M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $17.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $36.99M derived: sum of 2 quarters · filed 2026-02-19 | $56.24M derived: sum of 3 quarters · filed 2026-02-19 | $74.61M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $19.75M 10-Q · filed 2025-11-04 | $39.00M derived: sum of 2 quarters · filed 2025-11-04 | $57.38M 10-Q · filed 2025-11-04 | $73.88M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-06-30 | $19.24M 10-Q · filed 2025-08-07 | $37.62M 10-Q · filed 2025-08-07 | $54.13M derived: sum of 3 quarters · filed 2026-02-19 | $81.07M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-03-31 | $18.38M 10-Q · filed 2025-05-06 | $34.89M derived: sum of 2 quarters · filed 2026-02-19 | $61.83M derived: sum of 3 quarters · filed 2026-02-19 | $91.20M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2023-12-31 | $16.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $43.45M derived: sum of 2 quarters · filed 2026-02-19 | $72.82M derived: sum of 3 quarters · filed 2026-02-19 | $101.64M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $26.94M 10-Q · filed 2024-11-07 | $56.31M derived: sum of 2 quarters · filed 2024-11-07 | $85.13M 10-Q · filed 2024-11-07 | $112.47M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $29.37M 10-Q · filed 2024-08-08 | $58.19M 10-Q · filed 2024-08-08 | $85.53M derived: sum of 3 quarters · filed 2025-02-27 | $114.20M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $28.82M 10-Q · filed 2024-04-25 | $56.16M derived: sum of 2 quarters · filed 2025-02-27 | $84.83M derived: sum of 3 quarters · filed 2025-02-27 | $112.56M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $27.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $56.01M derived: sum of 2 quarters · filed 2025-02-27 | $83.74M derived: sum of 3 quarters · filed 2025-02-27 | $110.33M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $28.67M 10-Q · filed 2023-10-26 | $56.40M derived: sum of 2 quarters · filed 2023-10-26 | $82.99M 10-Q · filed 2023-10-26 | $109.22M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $27.73M 10-Q · filed 2023-08-03 | $54.32M 10-Q · filed 2023-08-03 | $80.56M derived: sum of 3 quarters · filed 2024-02-29 | $106.43M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $26.59M 10-Q · filed 2023-04-27 | $52.83M derived: sum of 2 quarters · filed 2024-02-29 | $78.70M derived: sum of 3 quarters · filed 2024-02-29 | $104.39M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $26.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $52.11M derived: sum of 2 quarters · filed 2024-02-29 | $77.81M derived: sum of 3 quarters · filed 2024-02-29 | $103.51M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $25.87M 10-Q · filed 2022-10-27 | $51.57M derived: sum of 2 quarters · filed 2022-10-27 | $77.28M 10-Q · filed 2022-10-27 | $98.69M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-06-30 | $25.70M 10-Q · filed 2022-08-04 | $51.41M 10-Q · filed 2022-08-04 | $72.82M derived: sum of 3 quarters · filed 2023-02-21 | $89.60M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-03-31 | $25.71M 10-Q · filed 2022-05-03 | $47.12M derived: sum of 2 quarters · filed 2023-02-21 | $63.90M derived: sum of 3 quarters · filed 2023-02-21 | $80.81M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2020-12-31 | $21.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $38.20M derived: sum of 2 quarters · filed 2023-02-21 | $55.10M derived: sum of 3 quarters · filed 2023-02-21 | $70.33M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $16.78M 10-Q · filed 2021-10-28 | $33.69M derived: sum of 2 quarters · filed 2021-10-28 | $48.91M 10-Q · filed 2021-10-28 | $60.38M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-06-30 | $16.91M 10-Q · filed 2021-07-29 | $32.13M 10-Q · filed 2021-07-29 | $43.60M derived: sum of 3 quarters · filed 2022-02-22 | $54.08M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-03-31 | $15.22M 10-Q · filed 2021-05-04 | $26.69M derived: sum of 2 quarters · filed 2022-02-22 | $37.17M derived: sum of 3 quarters · filed 2022-02-22 | $48.09M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2019-12-31 | $11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $21.95M derived: sum of 2 quarters · filed 2022-02-22 | $32.87M derived: sum of 3 quarters · filed 2022-02-22 | $42.13M 10-K · filed 2022-02-22 | |||
| 2019-09-30 | $10.48M 10-Q · filed 2020-10-29 | $21.40M derived: sum of 2 quarters · filed 2020-10-29 | $30.67M 10-Q · filed 2020-10-29 | $39.15M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $10.92M 10-Q · filed 2020-08-05 | $20.18M 10-Q · filed 2020-08-05 | $28.66M derived: sum of 3 quarters · filed 2021-02-25 | $37.60M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $9.26M 10-Q · filed 2020-04-30 | $17.74M derived: sum of 2 quarters · filed 2021-02-25 | $26.68M derived: sum of 3 quarters · filed 2021-02-25 | $34.77M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $17.42M derived: sum of 2 quarters · filed 2021-02-25 | $25.50M derived: sum of 3 quarters · filed 2021-02-25 | $33.25M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $8.94M 10-Q · filed 2019-10-30 | $17.03M derived: sum of 2 quarters · filed 2019-10-30 | $24.77M 10-Q · filed 2019-10-30 | $31.25M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $8.08M 10-Q · filed 2019-08-06 | $15.83M 10-Q · filed 2019-08-06 | $22.31M derived: sum of 3 quarters · filed 2020-03-02 | $29.48M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $7.75M 10-Q · filed 2019-05-02 | $14.22M derived: sum of 2 quarters · filed 2020-03-02 | $21.39M derived: sum of 3 quarters · filed 2020-03-02 | $29.28M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $6.48M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $13.64M derived: sum of 2 quarters · filed 2020-03-02 | $21.53M derived: sum of 3 quarters · filed 2020-03-02 | $30.56M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $7.17M 10-Q · filed 2018-11-05 | $15.05M derived: sum of 2 quarters · filed 2018-11-05 | $24.08M 10-Q · filed 2018-11-05 | $32.48M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $7.88M 10-Q · filed 2018-08-07 | $16.91M 10-Q · filed 2018-08-07 | $25.31M derived: sum of 3 quarters · filed 2019-03-01 | $34.27M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $9.03M 10-Q · filed 2018-05-09 | $17.43M derived: sum of 2 quarters · filed 2019-03-01 | $26.39M derived: sum of 3 quarters · filed 2019-03-01 | $35.12M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $17.36M derived: sum of 2 quarters · filed 2019-03-01 | $26.09M derived: sum of 3 quarters · filed 2019-03-01 | $35.01M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $8.96M 10-Q · filed 2017-11-02 | $17.70M derived: sum of 2 quarters · filed 2017-11-02 | $26.61M 10-Q · filed 2017-11-02 | $34.46M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2016-06-30 | $8.74M 10-Q · filed 2017-08-09 | $17.65M 10-Q · filed 2017-08-09 | $25.50M derived: sum of 3 quarters · filed 2018-03-06 | $33.55M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2016-03-31 | $8.91M 10-Q · filed 2017-05-08 | $16.76M derived: sum of 2 quarters · filed 2018-03-06 | $24.82M derived: sum of 3 quarters · filed 2018-03-06 | $33.15M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2015-12-31 | $7.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $15.90M derived: sum of 2 quarters · filed 2018-03-06 | $24.23M derived: sum of 3 quarters · filed 2018-03-06 | $33.98M 10-K · filed 2018-03-06 | |||
| 2015-09-30 | $8.05M 10-Q · filed 2016-11-03 | $16.38M derived: sum of 2 quarters · filed 2016-11-03 | $26.13M 10-Q · filed 2016-11-03 | $32.84M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $8.33M 10-Q · filed 2016-08-04 | $18.08M 10-Q · filed 2016-08-04 | $24.78M derived: sum of 3 quarters · filed 2017-03-16 | $29.40M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $9.75M 10-Q · filed 2016-05-05 | $16.45M derived: sum of 2 quarters · filed 2017-03-16 | $21.07M derived: sum of 3 quarters · filed 2017-03-16 | $25.35M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $11.33M derived: sum of 2 quarters · filed 2017-03-16 | $15.60M derived: sum of 3 quarters · filed 2017-03-16 | $19.31M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $4.62M 10-Q · filed 2015-11-09 | $8.90M derived: sum of 2 quarters · filed 2015-11-09 | $12.61M 10-Q · filed 2015-11-09 | $15.89M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $4.28M 10-Q · filed 2015-07-31 | $7.98M 10-Q · filed 2015-07-31 | $11.27M derived: sum of 3 quarters · filed 2016-02-29 | $13.91M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $3.71M 10-Q · filed 2015-05-05 | $6.99M derived: sum of 2 quarters · filed 2016-02-29 | $9.63M derived: sum of 3 quarters · filed 2016-02-29 | $11.51M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.92M derived: sum of 2 quarters · filed 2016-02-29 | $7.81M derived: sum of 3 quarters · filed 2016-02-29 | $8.43M 10-K · filed 2016-02-29 | $8.43M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | $2.64M 10-Q · filed 2014-11-06 | $2.64M 10-Q · filed 2013-11-14 | $4.52M derived: sum of 2 quarters · filed 2014-11-06 | $5.14M 10-Q · filed 2014-11-06 | $5.14M 10-Q · filed 2013-11-14 | $5.62M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | $1.88M 10-Q · filed 2014-08-07 | $2.50M 10-Q · filed 2014-08-07 | $2.98M derived: sum of 3 quarters · filed 2015-03-02 | $3.50M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2013-03-31 | $621.00K 10-Q · filed 2014-05-06 | $1.09M derived: sum of 2 quarters · filed 2015-03-02 | $1.61M derived: sum of 3 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $473.28K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $993.68K derived: sum of 2 quarters · filed 2015-03-02 | $2.29M 10-K · filed 2015-03-02 | $2.29M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | $520.40K 10-Q · filed 2013-11-14 | $1.82M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $1.29M 10-Q · filed 2013-08-13 | ||||||
| 2011-12-31 | $2.82M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |